Heart health under the microscope: landmark study on Gender-Affirming hormones

NCT ID NCT07128771

ENROLLING_BY_INVITATION Knowledge-focused Sponsor: University Hospital, Akershus Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study follows 450 people starting or continuing gender-affirming hormone therapy to see how it affects their heart and blood vessels over time. Researchers will use advanced heart scans, blood tests, and surveys to track changes. The goal is to provide clear information about cardiovascular risks and benefits to help patients and doctors make informed choices.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: gender-affirming hormone therapy
What this could lead to: If successful, this study could clarify whether gender-affirming hormone therapy is safe for the heart or increases cardiovascular risks, helping patients and doctors make informed decisions.
What could go wrong: This is an observational study, not a treatment trial, so it won't prove cause and effect. Results may take years and might not apply to everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARDIOVASCULAR DISEASE (CVD) RISK FACTORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cardiovascular disorder Gender Dysphoria heart disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CARDIOVASCULAR DISEASE (CVD) RISK FACTORS GENDER INCONGRUENCE

Contacts and locations

Locations

Oslo University Hospital

Oslo, Oslo, Norway

More trials for these conditions

Other studies related to the condition(s) this trial covers.